Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Collaborative arrangement revenue	$	1,752	$	1,136	$	4,606	$	3,291
Less:
OCU400	3,616		1,492		7,463		5,190
OCU410 and OCU410ST	1,373		759		3,675		2,598
NeoCart	19		104		25		459
COVAXIN	—		(65)		—		8
Inhaled mucosal vaccine platform	67		664		399		2,160
OCU200	131		48		530		324
Unallocated costs:
Research and development personnel costs	4,353		3,745		12,454		9,590
Facilities and other support costs	864		791		2,665		2,168
Other	726		570		1,870		1,339
Total research and development	11,149		8,108		29,081		23,836
General and administrative	8,228		6,280		21,446		20,372
Total operating expenses	19,377		14,388		50,527		44,208
Loss from operations	(17,625)		(13,252)		(45,921)		(40,917)
Other expense (income):
Interest Expense	(1,314)		$	(29)	(3,856)		(87)
Interest Income	207		$	310.00	778		843
Other (expense) income, net	(1,319)		$	1.00	(1,141)		(13)
Total other (expense) income	(2,426)		282		(4,219)		743
Segment and consolidated net loss	$	(20,051)	$	(12,970)	$	(50,140)	$	(40,174)